Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).

about

Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).

Item

http://www.wikidata.org/entity/Q50187344

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Randomized phase II study of a ...... tle cell lymphoma (RABBIT-14).

@en

Randomized phase II study of a ...... mphoma or mantle cell lymphoma

@nl

type

Item

label

Randomized phase II study of a ...... tle cell lymphoma (RABBIT-14).

@en

Randomized phase II study of a ...... mphoma or mantle cell lymphoma

@nl

prefLabel

Randomized phase II study of a ...... tle cell lymphoma (RABBIT-14).

@en

Randomized phase II study of a ...... mphoma or mantle cell lymphoma

@nl

P1476

Randomized phase II study of a ...... tle cell lymphoma (RABBIT-14).

@en

P2093

Hideki Tsujimura

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Irisawa

http://www.w3.org/2001/XMLSchema#string

Hisashi Wakita

http://www.w3.org/2001/XMLSchema#string

Kuniaki Itoh

http://www.w3.org/2001/XMLSchema#string

Kunihiro Tsukasaki

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Aotsuka

http://www.w3.org/2001/XMLSchema#string

Shinichi Masuda

http://www.w3.org/2001/XMLSchema#string

Tadahiko Igarashi

http://www.w3.org/2001/XMLSchema#string

Yoshikazu Utsu

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Bendamustine: rebirth of an old drug.

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel.

P304

1-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1390233

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29081255

http://www.w3.org/2001/XMLSchema#string